This early phase I trial evaluates blood samples to see if patients undergoing standard of care treatment with either stereotactic body radiation therapy or percutaneous ablation (using radio waves to create heat to destroy the tumor), have an increase in serum immune markers in kidney cancer. Information gained from this study may help doctors make treatment decisions for patients with kidney cancer.
Inclusion Criteria:
Histological diagnosis of primary RCC
Histological or radiographic diagnosis of metastatic RCC
Age >= 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0-3
Feasible vascular access as determined by study staff
Undergoing standard of care SBRT or PCA to RCC metastatic lesion(s)
Provide written informed consent
Willing to consent to research blood draws
Willing to return to enrolling institution for follow-up
Exclusion Criteria:
Prior local treatment of the index metastatic lesion
Pregnant or nursing women
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for study entry
| Facility | Status | Contact |
|---|---|---|
|
Facility
Mayo Clinic in Rochester
Rochester, Minnesota 55905
United States
Status
Recruiting
|
Recruiting |